Health Hims & Hers Launches Peptides+ With Five Unapproved Compounded Treatments November 19, 2026 Hims & Hers Enters the Booming Peptide Market Hims & Hers Health (NYSE: HIMS) announced on Wednesday the launch of Peptides+, a new specialty built around clinically guided protocols. The…